Lifestyle Drugs Market Outlook: Key Indications, Epidemiology, and Emergent Drugs

Table of Contents

• Introduction
• Alcohol Dependence
• Alopecia
• Obesity
• Oral Contraception
• Sexual Dysfunction
• Skin Aging
• Smoking Cessation

• Summary
• Introduction
• Defining the Market
• Defining Lifestyle Conditions
• Social Characteristics
• Disease characteristics
• Product Characteristics

• Sales Potential
• High demand upon launch
• Ability to create new markets

• Drivers of demand for lifestyle drugs
• An aging population
• Growth in disposable income
• Increasing consumer awareness
• Rise in branding activities

• Barriers to market growth
• Demonstrating favorable health economics to payors - the road to rationing
• Drug abuse and misuse
• Loss of corporate control over brand

• Reimbursement
• Recommendations for securing reimbursement of lifestyle drugs
• Data Caveats

• Summary
• Overview of Alcohol Dependence
• Diagnosis
• Measuring & Diagnosing
• Pathophysiology
• Factors Influencing Severity of Symptoms
• Gender Influence
• Genetic Influence
• Prevalence
• Reimbursement

• Drug Therapy
• Disulfiram (Aldehyde Dehydrogenase Inhibitor)
• Naltrexone
• Benzodiazepines
• Sodium Oxybate
• Acamprosate
• Metadoxine

• Market Analysis
• Campral (Acamprosate)
• Antabuse
• Naltrexone Therapies
• Pipeline Outlook

• Summary
• Overview of Alopecia
• Pathophysiology & Etiology
• Alopecia areata
• Androgenetic alopecia
• Anagen effluvium
• Telogen effluvium
• Scarring alopecia
• Self-induced alopecia
• Other causes

• Prevalence
• Drug Therapy
• Market Analysis
• Propecia
• Rogaine (minoxidil)
• Pipeline Outlook

• Summary
• Overview of Obesity
• Definition
• Measuring & Diagnosing Obesity
• Pathophysiology & etiology
• Factors influencing severity of Obesity
• Age and Gender Influence
• Genetic Influence
• Nutritional Influence
• Prevalence
• Reimbursement
• Drug Therapy
• Market Analysis
• Xenical
• Reductil/Meridia/Ectiva (sibutramine)
• Acomplia (Rimobant)
• Company Analysis
• Pipeline Outlook
• Novel Mechanisms

• Summary
• Overview of Oral Contraception
• The female reproductive population
• Drug therapy
• Side Effect Profile

• Market Analysis
• The Yasmin Franchise
• Ortho Tri-cyclen Lo
• Estrostep Fe
• Ortho Evra
• Mirena
• Seasonale
• Reimbursement
• Promotional Spend
• Company Analysis
• Pipeline Outlook

• Summary
• Overview of Sexual Dysfunction
• Male Sexual Dysfunction
• Diagnosis
• Pathophysiology & diagnostic indicators
• Erectile dysfunction (ED)
• Loss of libido
• Priapism
• Peyronie' s disease
• Premature and delayed ejaculation
• Contributing Factors
• Prevalence
• Reimbursement
• Drug Therapy
• PDE-5 Inhibitors
• Alprostadil

• Market Analysis
• Viagra
• Cialis
• Levitra

• Promotional Spend
• Product Pipeline
• Delivery Mechanism
• Niche Markets
• OTC Retail
• Phosphodiesterase Inhibitors

• Female sexual Dysfunction
• Diagnosis
• Sexual desire disorders
• Female sexual arousal disorder
• Sexual orgasmic disorder
• Sexual pain disorders

• Measuring & diagnosing
• Factors influencing the severity of female sexual dysfunction
• Genetic Influence
• Prevalence
• Drug Therapy
• Pipeline outlook

• Summary
• Overview of Skin Aging
• Pathophysiology and etiology
• Factors Driving Demand
• Demographic Influence
• Personal Appearance Gain
• Acceptance of Cosmetic Procedures

• Prevalence
• Drug Therapy
• Market Analysis
• Renova (tretinoin)
• Retin-A/Retin-A Micro (tretinoin)
• Botox (botulinum toxin type A)
• Tazarotene
• Company Activities
• Product Pipeline

• Summary
• Overview of smoking cessation
• Measuring & Diagnosing
• Pathophysiology & etiology
• Factors influencing smoking cessation
• Prevalence
• Policy & Reimbursement
• Drug Therapy
• Nicotine replacement therapy
• Antidepressants
• Nicotine partial receptor agonists

• Market Analysis
• Champix/Chantix (US)
• Nicotine Replacement Therapies
• Zyban
• Promotional Spend
• Company Analysis
• Pipeline Outlook
• Opioid Receptor Agonists
• Cannabinoid Receptor Antagonists
• Clonidine
• Nicotine Conjugate Vaccine
• Glycine Receptor Antagonist

• IMS data
  • Alcohol Dependence
  • Alopecia
  • Obesity
  • Oral Contraception
  • Sexual Dysfunction
  • Smoking Cessation
• Pearl Index
• Index

• Figure 1.1: Defining Lifestyle Drugs
• Figure 1.2: The reimbursement decision process
• Figure 1.3: Improving reimbursement status of lifestyle drugs: a three-pronged approach
• Figure 2.4: Geographic market shares for Alcohol Dependence Drugs by sales revenue, 2006 ($m)
• Figure 2.5: Pipeline for alcohol dependence therapies, 2007
• Figure 3.6: Pipeline for alopecia therapies, 2007
• Figure 4.7: Geographic market shares for anti-obesity products by sales revenue, 2006 ($m)
• Figure 4.8: Pipeline for obesity therapies, 2007
• Figure 5.9: Revenues by drug class for prescription oral contraceptives ($m), 2006; EU5, Japan, USA
• Figure 5.10: Geographic market sizes for prescription oral contraceptives by sales revenue, 2006 ($m)
• Figure 5.11: Promotional spend on top oral contraceptive brands in major markets (EU5, USA), 2006 ($m)
• Figure 5.12: Pipeline for oral contraceptives, 2007
• Figure 6.13: Geographic market size for erectile dysfunction products by sales revenue, 2006,($m)
• Figure 6.14: Pipeline for erectile dysfunction therapies, 2007
• Figure 6.15: Possible caused of female sexual dysfunction
• Figure 6.16: Pipeline for female sexual dysfunction therapies, 2007
• Figure 7.17: Factors influencing cosmeceutical consumption across the major markets
• Figure 7.18: Demographics of skin aging concerns
• Figure 7.19: Pipeline for skin aging therapies, 2007
• Figure 8.20: Global sales of smoking cessation drugs, 2006 ($m)
• Figure 8.21: Pipeline for smoking cessation products, 2007

• Table 1.1: Distribution channels covered in IMS MIDAS database
• Table 2.2: Top 10 Alcohol dependency therapies 2007, Growth Metrics
• Table 2.3: Pipeline analysis; alcohol dependence therapies
• Table 3.4: Drug therapy for common types of alopecia
• Table 3.5: Top 10 alopecia brands 2007, growth metrics
• Table 4.6: Classification of overweight, obesity by BMI, waist circumference and associated disease risk
• Table 4.7: Obesity-linked Genotypes
• Table 4.8: Projected prevalence of obesity, 2006-2012 (' 000s)
• Table 4.9: Top 10 anti-obesity brands 2007, growth metrics
• Table 4.10: Obesity pipeline products
• Table 5.11: Forecast growth of the childbearing population; EU5, US and Japan, 2007-10 (000s)
• Table 5.12: Top 10 oral contraceptive brands, 2007 ($m)
• Table 6.13: Common physiological causes of erectile dysfunction
• Table 6.14: Prevalence of moderate and severe ED in the seven major markets
• Table 6.15: Top 5 erectile dysfunction brands 2007; growth metrics
• Table 6.16: Pipeline analysis; female sexual dysfunction (FSD)
• Table 7.17: Symptoms of skin aging
• Table 8.18: Factors influencing smoking cessation success
• Table 8.19: Smoking prevalence; EU5, US, Japan; 2002
• Table 8.20: Top 10 smoking cessation brands 2007, growth metrics